Allos Therapeutics To Hold Third Quarter 2004 Financial Results Conference Call and Webcast on Tuesday, November 9

Allos Therapeutics To Hold Third Quarter 2004 Financial Results
Conference Call and Webcast on Tuesday, November 9 


WESTMINSTER, Colo., Nov. 4  /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc.
(NASDAQ:ALTH) will hold a conference call Tuesday, November 9, 2004, at 11:00
AM ET to discuss its third quarter 2004 financial results.

   Time:              11:00 AM ET
   Date:              Tuesday, November 9, 2004
   Dial-in:           [phone] Domestic / [phone] International
   Participant code:  123530
   Webcast:           http://www.allos.com/
                      (homepage and investor relations section)



Interested parties unable to participate in the live conference call may access
a recorded rebroadcast by dialing 877-660-6853 (domestic) or [phone]
(international); the pass code number is 123530.  The replay will be available
from 1:00 PM ET on Tuesday, November 9, 2004 until 11:59 PM ET on November 16,
2004.  In addition, the webcast will be archived for 30 days at
http://www.allos.com/ .

Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing
and commercializing innovative drugs for improving cancer treatments. The
company's lead clinical candidate, EFAPROXYN(TM), is a synthetic small molecule
that has the potential to sensitize hypoxic (oxygen deprived) tumor tissues and
enhance the efficacy of standard radiation therapy. In addition, Allos is
developing PDX (pralatrexate), a novel small molecule cytoxic injectable
antifolate (DHFR inhibitor) that is currently being investigated in patients
with non-small cell lung cancer and non- Hodgkin's lymphoma. For more
information, please visit the company's web site at: http://www.allos.com/ . 

DATASOURCE: Allos Therapeutics, Inc.



CONTACT:  Jennifer Neiman, (media) Corporate Communications of Allos

Therapeutics, Inc., [phone],  



Web site:  http://www.allos.com/ 

Copyright